{
  "drugs": [
    {
<<<<<<< Updated upstream
      "drug": "VS-7375 (GFH375)",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Oral KRAS G12D ON/OFF inhibitor",
      "fda_status": "Fast track (PDAC)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Daraxonrasib (RMC-6236)",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "RAS(ON) multi-selective inhibitor",
      "fda_status": "Breakthrough therapy (PDAC)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Tipifarnib",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Farnesyltransferase inhibitor",
      "fda_status": "Phase II (no approval)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Simvastatin",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Inhibits KRAS prenylation",
      "fda_status": "Approved for hypercholesterolemia",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Metformin",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Activates AMPK inhibiting KRAS-driven proliferation",
      "fda_status": "Approved for type 2 diabetes",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Aspirin",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Blocks NF-ÎºB pathway downstream of KRAS",
      "fda_status": "Approved for anti-inflammatory use",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Propranolol",
      "proteins": [
        "CD44"
      ],
      "mechanism": "Reduces CD44-mediated stemness",
      "fda_status": "Approved for hypertension",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Doxycycline",
      "proteins": [
        "CD44"
      ],
      "mechanism": "Inhibits CD44-dependent invasion",
      "fda_status": "Approved for infections",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Losartan",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Disrupts KRAS-fibroblast activation",
      "fda_status": "Approved for hypertension",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Itraconazole",
      "proteins": [
        "KRAS",
        "CD44"
      ],
      "mechanism": "Inhibits KRAS-GLI1 axis and CD44-mediated angiogenesis",
      "fda_status": "Approved for antifungal use",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Thalidomide",
      "proteins": [
        "CD44"
      ],
      "mechanism": "Downregulates CD44 expression",
      "fda_status": "Approved for multiple myeloma",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Disulfiram",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Chelates copper to block KRAS activity",
      "fda_status": "Approved for alcohol aversion",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Cimetidine",
      "proteins": [
        "CD44",
        "CA19-9"
      ],
      "mechanism": "Blocks CD44-E-selectin adhesion",
      "fda_status": "Approved for GERD",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Atenolol",
      "proteins": [
        "CD44"
      ],
      "mechanism": "Suppresses stress-induced CD44 upregulation",
      "fda_status": "Approved for hypertension",
      "category": "repurposing_candidate"
=======
      "drug": "sotorasib",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Covalent binding to GDP-bound KRAS G12C",
      "fda_status": "Approved (NSCLC, CRC combo)"
    },
    {
      "drug": "adagrasib",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Covalent binding to GDP-bound KRAS G12C",
      "fda_status": "Approved (NSCLC, CRC)"
    },
    {
      "drug": "daraxonrasib (RMC-6236)",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "RAS(ON) multi-selective; binds active GTP-RAS",
      "fda_status": "Breakthrough Therapy (PDAC)"
    },
    {
      "drug": "MRTX1133",
      "proteins": [
        "KRAS G12D"
      ],
      "mechanism": "Direct switch-II pocket binding to KRAS G12D",
      "fda_status": "Phase 1/2 (PDAC)"
    },
    {
      "drug": "VS-7375 (GFH375)",
      "proteins": [
        "KRAS G12D"
      ],
      "mechanism": "Oral direct KRAS G12D inhibition",
      "fda_status": "Fast Track (PDAC)"
    },
    {
      "drug": "zoldonrasib",
      "proteins": [
        "KRAS G12D"
      ],
      "mechanism": "Direct KRAS G12D inhibition",
      "fda_status": "Entering clinic"
>>>>>>> Stashed changes
    }
  ],
  "cancer_type": "pancreatic cancer",
  "protein_targets": [
    "KRAS",
<<<<<<< Updated upstream
    "CD44",
    "CA19-9"
=======
    "KRAS G12D",
    "CD44"
>>>>>>> Stashed changes
  ]
}